Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Discloses Siegel s New Salary; WellGen s Evans Dies; Stanford s Len Herzenberg Wins Kyoto Prize; Motif Taps New CEO; and Others

David Evans, WellGen 's CEO, died on June 1 following a brief illness, the company said on Monday.


The board of directors will meet to decide on a replacement. Until then, Arthur Finnel, the chief financial officer, will assume day-to-day operations.


Evans joined WellGen in 1999 as CEO and president. Until then, he was a vice-president of business and product development at DNA Plant Technology, a company he co-founded.


Evans earned his BS, MS, and PhD from Ohio State University and completed the PMD at Harvard Business School.

Motif BioSciences has named Zaki Hosny deputy chairman and chief executive officer effective July 1.


Hosny comes to Motif from Merck , where he was vice president of marketing and operations for Europe, the Middle East, and Africa.

Hosny succeeds Stephen Cass as CEO. Cass is a managing director of Amphion , which owns Motif. He will remain on Motif's payroll as vice president for business development.

Hosny has an MA in history and law from CambridgeUniversityin Cambridge, UK.

Nonlinear Dynamics has appointed Christian Stahlberg as applications specialist, the company said on Monday.


Stahlberg comes to Nonlinear from GE Healthcare where he was most recently managed the DeCyder Extended Data Analysis project.

Quantum Genomics named Lionel Ségard as its new chief executive officer, the company said Tuesday.


Ségard will lead Quantum Genomics to develop new therapeutics projects, the company said in a statement. Quantum Genomics has already earmarked 3 million ($3.8 million) to begin identifying and selecting research projects in Europe.


Ségard served as CEO of Inserm-Transfert, Inserm's technology-transfer arm, until March 2006. He is a founding member of France's Strategic Council for Innovation, where he was secretary general from 2003 to 2005. He was also the CEO of the French subsidiary of a US information technology company, 24/7 Media from 1999 to 2002. Finally, he co-founded Eurobiobiz.

Affymetrix listed Susan Siegel's compensation package as president emeritus in documents filed with the Securities and Exchange Commission last week.


Siegel will receive an annual base salary of $426,315. If her employment ends before Nov. 19, 2007, she will receive a cash payment equal to $675,000 less the salary she received starting April 19. In addition, her health coverage will last until Oct. 19, 2007. Her stock options will continue its accelerated vesting as if she'd remained with the company until that date.

Cognia appointed Robert Merold as the new chief executive officer and David Rubin as chief scientific officer and senior vice-president of product management, the company said on Wednesday.


Merold has been on Cognia's board of directors since 2002, and is a healthcare information and software business consultant. Previously he was the chief operating officer and board member of Proteome before it was sold to Incyte Genomics in 2001. He has held executive positions at IMS Health, Bristol-Myers Squibb and Procter & Gamble.


Rubin, a Cognia founder, has held positions at IBM Global Services and The Wilkerson Group.

The board of directors elected Alan Holmer as its new member, NanoInk said yesterday.


Holmer is the former president and chief executive officer of the Pharmaceutical Research and Manufacturers of America. He is a member of the Presidential Advisory Council on HIV and AIDS and Inspire Pharmaceuticals' board of directors.


Holmer was a partner at Sidley & Austin and an associate at Steptoe & Johnson. He received an AB degree from Princeton University and a JD from Georgetown University.

Enzo Biochem appointed Carl Balezentis as president of Enzo Life Sciences, its wholly owned subsidiary, the company said yesterday.


Formerly, Balezentis was chief executive officer of Lark Technologies prior to its acquisition by Genaissance Pharmaceuticals. After the acquisition, he joined Genaissance as a senior vice-president. Prior to Lark, he was director of business development at Sigma-Aldrich's life sciences division. He was vice-president of sales and marketing at Genosys Biotechnologies prior to its acquisition by Sigma-Aldrich.


Balezentis was a director of marketing at Perceptive Scientific Instruments before its acquisition by International Remote Imaging Systems, and a group leader for human identity products at Applied Biosystems.

The Biotechnology Institute named Invitrogen's Peter Leddy to its board of directors, the organization said on Wednesday.


Leddy is senior vice-president of human resources, a position he's held since July 2005. Prior to Invitrogen, Leddy spent five years with Dell in several management positions, most recently vice-president of human resources for Americas Operations.


He received his BA in psychology from Creighton University and his MS and PhD in industrial/organizational psychology from the Illinois Institute of Technology.

Cambridge, UK-based NextGen Group has appointed Geoff Alms as sales director for North America and Gareth Thomson as head of marketing, the company said yesterday.


Alms came to NextGen Science from Upstate, a division of Serologicals, where he was employed director of sales for drug discovery for the North America region. Alms completed his PhD and postdoctoral studies in pharmacology at the University of Virginia.


Along with Alms, three salesmen were appointed to create a technically qualified sales team in the US.


Prior to NextGen, Thomson was senior marketing manager for Affymetrix UK. He was also at Amersham-Pharmacia Biotech, now GE Healthcare. He holds a BSc in biological sciences from Salford University in Manchester, England.

Leonard Herzenberg, Stanford's professor emeritus of genetics, has won the 2006 Kyoto Prize, Japan's equivalent of the Nobel Prize, said the Stanford University School of Medicine.


The Inamori Foundation awards three Kyoto Prizes annually to individuals and groups worldwide who have contributed significantly to human progress in advanced technology, basic sciences, and arts and philosophy. This year's winners were announced today and the official award ceremony will take place Nov. 10 in Kyoto, Japan. Each winner will receive a 20-karat gold medal and a cash gift of approximately $446,000.


Herzenberg won the advanced technology prize for his work on the fluorescence-activated cell sorter. In the late 1960s, Herzenberg directed the development of the first FACS machine, and on later commercialization efforts.


The husband and wife team, known to colleagues as Len and Lee, have worked together Herzenberg's days at California Institute of Technology. Herzenberg completed a postdoctoral fellowship with Jacques Monod at the Pasteur Institute in Paris and served as a public health service officer at the National Institutes of Health in Harry Eagle's laboratory. In 2004, he received the Novartis Prize in Immunology.

As GenomeWeb News reported last month, Invitrogen has created a Flow Cytometry Scientifc Advisory Board and Herzenberg as chairman. His wife will join the board as a member.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.